Sugi Predict

Sugi Predict / Compounds / SCHEMBL497530

SCHEMBL497530

SCHEMBL497530

O=C1NC(=S)SC1=Cc1ccc2c(c1)OCO2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK2A2 P19784 2/20 0.67
▸ CSNK2B P67870 2/20 0.67
▸ CSNK2A1 P68400 2/20 0.67
▸ DYRK1A Q13627 2/20 0.67
▸ DYRK1B Q9Y463 2/20 0.67
▸ CLK1 P49759 1/20 0.67
▸ DYRK2 Q92630 1/20 0.67
▸ GSK3B P49841 1/20 0.64
▸ KMT2A Q03164 3/20 0.61
▸ MEN1 O00255 2/20 0.61
▸ CDC25B P30305 1/20 0.61
▸ CSNK2A3 Q8NEV1 1/20 0.61
▸ NAT1 P18440 5/20 0.60
▸ MYC P01106 2/20 0.60
▸ MAX P61244 2/20 0.60
▸ MAPK9 P45984 1/20 0.60
▸ RAB9A P51151 2/20 0.59
▸ NPC1 O15118 1/20 0.59
▸ CASP3 P42574 1/20 0.59
▸ SENP8 Q96LD8 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL497529 1.00 CSNK2A2 (0.67) CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B
SCHEMBL1520306 1.00 CSNK2A2 (0.67) CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B
SCHEMBL30250232 0.92 GSK3B (0.77) CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B
SCHEMBL8177487 0.87 CSNK2A2 (0.54) CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B
SCHEMBL29369746 0.87 GSK3B (0.83) CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B
SCHEMBL1249096 0.87 GSK3B (0.83) CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B
SCHEMBL1249098 0.87 GSK3B (0.83) CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B
SCHEMBL2882197 0.87 GSK3B (0.83) CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B
SCHEMBL497019 0.83 DYRK1A (0.67) CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B
SCHEMBL497020 0.83 DYRK1A (0.67) CSNK2A2CSNK2BCSNK2A1DYRK1ADYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7846925-B2 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2010-12-07 — — US claimed
EP-2227233-A2 IDO INHIBITORS Newlink Genetics (US) 2010-09-15 — — EP claimed
WO-2009073620-A2 IDO INHIBITORS NEWLINK GENETICS (US) 2009-06-11 — — WO claimed
US-20090042773-A1 P13 kinase gamma inhibitors for the treatment of anaemia MERCK SERONO SA (CH) 2009-02-12 — — US claimed
EP-1807075-A2 PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA Applied Research Systems ARS Holding N.V. (AN) 2007-07-18 — — EP claimed
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2006-06-08 — — US claimed
WO-2006040318-A2 PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2006-04-20 — — WO claimed
US-20050222225-A1 Use of compounds for increasing spermatozoa motility APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) 2005-10-06 — — US claimed
US-20130289083-A1 IDO Inhibitors NEWLINK GENETICS CORPORATION 2013-10-31 — — US disclosed
US-8106214-B2 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as PI3 kinase inhibitors MERCK SERONO SA (CH) 2012-01-31 — — US disclosed
US-20110053941-A1 IDO Inhibitors NEWLINK GENETICS (US) 2011-03-03 — — US disclosed
US-7846925-B2 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2010-12-07 — — US disclosed
US-20090306069-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES LABORATOIRES SERONO S.A. (CH) 2009-12-10 — — US disclosed
EP-1648452-B1 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS MERCK SERONO SA (CH) 2009-07-22 — — EP disclosed
WO-2000018748-A1 RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS ROCHE DIAGNOSTICS GMBH (DE) 2000-04-06 — — WO disclosed
EP-0915090-A1 Compounds useful as hypoglycemic agents and for treating Alzheimer's disease ELI LILLY AND COMPANY (US) 1999-05-12 — — EP disclosed
US-5716975-A NONTOXIC RHODANINE DERIVATIVES; ANTIDIABETIC AGENTS, CATHEPSIN D INHIBITORS, B-AMYLOID PROTEIN REDUCTION ELI LILLY AND COMPANY (US) 1998-02-10 — — US disclosed
US-5661168-A ADMINISTERING RHODANINE DERIVATIVES TO CONTROL DIABETES ELI LILLY AND COMPANY (US) 1997-08-26 — — US disclosed
US-5523314-A RHODANINE DERIVATIVES ELI LILLY AND COMPANY (US) 1996-06-04 — — US disclosed
EP-0587377-A2 Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease ELI LILLY AND COMPANY (US) 1994-03-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306069-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES ZAP70, BRCA1, ZYX CSNK2A2 4143/4885CSNK2B 3684/4885CSNK2A1 4079/4885
US-20090042773-A1 P13 kinase gamma inhibitors for the treatment of anaemia PDPK1, PRKD3, PRKD1 CSNK2A2 388/4885CSNK2B 423/4885CSNK2A1 353/4885
US-20110053941-A1 IDO Inhibitors IDO1, IDO2, INMT CSNK2A2 3199/4885CSNK2B 3130/4885CSNK2A1 3460/4885
US-20050222225-A1 Use of compounds for increasing spermatozoa motility CATSPER1, PI4KB, MAN2B2 CSNK2A2 338/4885CSNK2B 297/4885CSNK2A1 296/4885
US-20130289083-A1 IDO Inhibitors IDO1, IDO2, INMT CSNK2A2 3464/4885CSNK2B 3387/4885CSNK2A1 3613/4885
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives BRCA1, ZAP70, F13B CSNK2A2 4161/4885CSNK2B 3849/4885CSNK2A1 4103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.